{"id":"cinchophen","rwe":[{"pmid":"40807476","year":"2025","title":"Synthesis and Biological Activity of Novel Polyazaheterocyclic Derivatives of Quinine.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"38306819","year":"2024","title":"Cinchophen induces RPA1 related DNA damage and apoptosis to impair ENS development of zebrafish.","finding":"","journal":"Ecotoxicology and environmental safety","studyType":"Clinical Study"},{"pmid":"34675254","year":"2021","title":"Potential efficacy of existing drug molecules against severe fever with thrombocytopenia syndrome virus: an in silico study.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"30650218","year":"2019","title":"Rh(III) -Catalyzed Straightforward Synthesis of Benzophenanthroline and Benzophenanthrolinone Derivatives using Anthranils.","finding":"","journal":"Chemistry (Weinheim an der Bergstrasse, Germany)","studyType":"Clinical Study"},{"pmid":"29317149","year":"2018","title":"Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.","finding":"","journal":"Bioorganic & medicinal chemistry","studyType":"Clinical Study"}],"tags":[{"label":"cinchophen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","category":"target"},{"label":"PDE10A","category":"gene"},{"label":"M04AC02","category":"atc"},{"label":"Active","category":"status"},{"label":"Gout","category":"indication"},{"label":"Anesthetics","category":"pharmacology"},{"label":"Anesthetics, Local","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CINCHOPHEN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:24:47.925154+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Cinchophen","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:24:56.023886+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:25:04.025594+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:24:53.147891+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CINCHOPHEN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:24:54.947197+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL348000/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:24:55.659727+00:00"}},"allNames":"cincain","offLabel":[],"synonyms":["phenylcinchoninic acid","cincain","cinchophen","aciphenochinoline","aciphenochinolinium","cinchophene","cinchophenic acid","cinconal","cincophen","phenoquin","quinofen","quinophan","quinophen"],"timeline":[],"aiSummary":"Cinchophen (Cincain) is a marketed drug primarily indicated for gout, positioned in a competitive landscape alongside colchicine, which has been FDA-approved since 1961 and is patent-protected until October 6, 2028. Its key strength lies in its unique mechanism of action, blocking the enzyme that degrades cAMP and cGMP, potentially offering a distinct therapeutic benefit. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[],"brandName":"Cincain","ecosystem":[{"indication":"Gout","otherDrugs":[{"name":"allopurinol","slug":"allopurinol","company":"Prometheus Labs"},{"name":"colchicine","slug":"colchicine","company":"Merck"},{"name":"indomethacin","slug":"indomethacin","company":""},{"name":"naproxen","slug":"naproxen","company":"Roche Palo"}],"globalPrevalence":41000000}],"mechanism":{"target":"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","targets":[{"gene":"PDE10A","source":"DrugCentral","target":"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","protein":"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A"}],"modality":"Small Molecule","drugClass":"cinchophen","explanation":"","oneSentence":"","technicalDetail":"Cinchophen specifically targets and inhibits cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, a phosphodiesterase enzyme responsible for the hydrolysis of cAMP and cGMP, leading to increased levels of these second messengers and subsequent downstream effects."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cinchocaine","title":"Cinchocaine","extract":"Cinchocaine (INN/BAN) or dibucaine (USAN) is an amide local anesthetic. Among the most potent and toxic of the long-acting local anesthetics, current use of cinchocaine is generally restricted to spinal and topical anesthesia. It is sold under the brand names Cincain, Nupercainal, Nupercaine and Sovcaine."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3101","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CINCHOPHEN","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Cinchocaine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:02:05.706233","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:25:04.025689+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"colchicine","drugSlug":"colchicine","fdaApproval":"1961-07-27","patentExpiry":"Oct 6, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"cinchophen","indications":{"approved":[{"name":"Gout","source":"DrugCentral","snomedId":90560007,"regulator":"FDA","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"colchicine","brandName":"colchicine","genericName":"colchicine","approvalYear":"1961","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"39Y533Z02M","CHEBI":"CHEBI:114195","INN_ID":"1332","UMLSCUI":"C0008793","chemblId":"CHEMBL348000","ChEMBL_ID":"CHEMBL348000","KEGG_DRUG":"D07280","DRUGBANK_ID":"DB13551","PUBCHEM_CID":"8593","SNOMEDCT_US":"61709008","MESH_DESCRIPTOR_UI":"D003992","MESH_SUPPLEMENTAL_RECORD_UI":"C084834"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":219,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M04AC02","allCodes":["M04AC02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Aug 7","pmid":"40807476","title":"Synthesis and Biological Activity of Novel Polyazaheterocyclic Derivatives of Quinine.","journal":"Molecules (Basel, Switzerland)"},{"date":"2024 Mar 1","pmid":"38306819","title":"Cinchophen induces RPA1 related DNA damage and apoptosis to impair ENS development of zebrafish.","journal":"Ecotoxicology and environmental safety"},{"date":"2021 Oct 21","pmid":"34675254","title":"Potential efficacy of existing drug molecules against severe fever with thrombocytopenia syndrome virus: an in silico study.","journal":"Scientific reports"},{"date":"2019 Feb 26","pmid":"30650218","title":"Rh(III) -Catalyzed Straightforward Synthesis of Benzophenanthroline and Benzophenanthrolinone Derivatives using Anthranils.","journal":"Chemistry (Weinheim an der Bergstrasse, Germany)"},{"date":"2018 Feb 15","pmid":"29317149","title":"Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.","journal":"Bioorganic & medicinal chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:25:04.025689+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}